
NYSEHealthcareMedical - Diagnostics & Research
最新資料
US$170.54
+US$2.37 · +1.41%
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
前收盤價
US$170.54
+US$2.37 · +1.41%
盤中時間採用ET。市場資料可能有所延遲。
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
日內區間
目前US$170.54
52週區間
目前US$170.54
盤中時間採用ET。市場資料可能有所延遲。
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
日內區間
目前US$170.54
52週區間
目前US$170.54
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 69.48億 USD | 65.1億 USD | 68.33億 USD | 68.48億 USD | 63.19億 USD |
| 銷貨成本 | 33.05億 USD | 29.75億 USD | 33.68億 USD | 31.26億 USD | 29.12億 USD |
| 毛利 | 36.43億 USD | 35.35億 USD | 34.65億 USD | 37.22億 USD | 34.07億 USD |
| 研究與開發 | 4.55億 USD | 4.79億 USD | 4.81億 USD | 4.67億 USD | 4.41億 USD |
| 銷售、一般及管理費用 | 17.09億 USD | 15.18億 USD | 16.34億 USD | 16.37億 USD | 16.19億 USD |
| 營業費用 | 21.64億 USD | 20.47億 USD | 21.15億 USD | 21.04億 USD | 20.6億 USD |
| 利息收入 | 6200萬 USD | 8000萬 USD | 5100萬 USD | 900萬 USD | 200萬 USD |
| 利息支出 | 1.12億 USD | 9600萬 USD | 9500萬 USD | 8400萬 USD | 8100萬 USD |
| 折舊和攤銷 | 2.88億 USD | 2.57億 USD | 2.71億 USD | 3.17億 USD | 3.21億 USD |
| 營業利益 | 14.79億 USD | 14.88億 USD | 13.5億 USD | 16.18億 USD | 13.47億 USD |
| 淨利 | 13.03億 USD | 12.89億 USD | 12.4億 USD | 12.54億 USD | 12.1億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$171.67
上漲空間 0.66%年度分割調整後的每股現金分配。
US$0.956
2024年(完整年度)+42.3% 自從 2019
2026年(部分年度):US$1.02
US$0.672
2,019
US$0.776
2,021
US$1.065
2,022
US$0.911
2,023
US$0.956
2,024
US$1.02
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年10月6日 | US$0.255Quarterly | 2026年10月6日 | 2026年10月28日 |
股息 | 2026年6月30日 | US$0.255Quarterly | 2026年6月30日 | 2026年7月22日 |
股息 | 2026年3月31日 | US$0.255Irregular | 2026年3月31日 | 2026年4月22日 |
股息 | 2026年1月6日 | US$0.255Quarterly | 2026年1月6日 | 2026年1月28日 |
股息 | 2025年9月30日 | US$0.248Quarterly | 2025年9月30日 | 2025年10月22日 |
股息 | 2025年7月1日 | US$0.248Quarterly | 2025年7月1日 | 2025年7月23日 |
除息 2026年10月6日
US$0.255
Quarterly
2026年10月6日登記 · 支付日 2026年10月28日
除息 2026年6月30日
US$0.255
Quarterly
2026年6月30日登記 · 支付日 2026年7月22日
除息 2026年3月31日
US$0.255
Irregular
2026年3月31日登記 · 支付日 2026年4月22日
除息 2026年1月6日
US$0.255
Quarterly
2026年1月6日登記 · 支付日 2026年1月28日
除息 2025年9月30日
US$0.248
Quarterly
2025年9月30日登記 · 支付日 2025年10月22日
除息 2025年7月1日
US$0.248
Quarterly
2025年7月1日登記 · 支付日 2025年7月23日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T920.83億0.07%129.35兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI13.78億0.06%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO11.53億0.07%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO9.37億0.41%2264億 USD0.03%US$81.14+0.92%
iShares Core S&P 500 ETFIVV6.31億0.07%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY5.82億0.07%8172億 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV4.14億0.16%2624億 USD0.03%US$220.59+0.44%
State Street Health Care Select Sector SPDR ETFXLV3.38億0.78%435.37億 USD0.08%US$170.81+1.58%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLVAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。